A new paradigm for targeting mutant p53 tumours

靶向突变 p53 肿瘤的新范例

• 批准号: nhmrc : GNT1120293
• 负责人: Dr Carleen Cullinane
• 金额: $ 90.17万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-paradigm-targeting-p53-tumours/1347117
• 关键词: new; paradigm; targeting; mutant; p53

Over half of all cancers contain mutations in a gene called TP53, also known as the “guardian of the genome”. Mutation of TP53 provides tumour cells with a growth advantage, and leads to resistance to chemotherapy and poor outcomes for patients. We have identified a potential “Achilles heel” in cancers with TP53 mutations. In this project we will establish a new paradigm for treating tumours with TP53 mutations that will be applicable to a large number of patients across all types of cancer.

超过一半的癌症都含有一种叫做TP53的基因突变，TP53也被称为“基因组的守护者”。TP53的突变为肿瘤细胞提供了生长优势，并导致对化疗的耐药性和患者的不良结局。我们已经确定了TP53突变癌症的潜在“致命弱点”。在这个项目中，我们将建立一个新的模式来治疗TP53突变的肿瘤，这将适用于所有类型的癌症的大量患者。